Bright Peak Therapeutics raises $90M in Series C round led by J&J Innovation – JJDC, Inc., with participation from Venrock, KB Investment, & Northleaf Capital Partners to advance next-gen #immunotherapies. Congratulations! jji.jnj/4c6UWCL

Hosting the first ever CEO Summit in our EMEA region is something we've been looking forward to, and we are excited to see the meaningful connections and inspiring insights that transpire from these sessions, all in the name of patient care.

We are proud of the impact that our commitment to fostering #oncology innovation has had over the past ten years. Do you have a potentially transformative idea in oncology? Find out how we can help bring it to reality: jji.jnj/3XMIHqy

Join Johnson & Johnson Innovation & DealForma for a webinar on the latest trends in biopharma dealmaking and funding through Q2 2024. Don't miss this opportunity to gain valuable insights from an industry expert. Register now! jji.jnj/3VPyR6e

Our regional incubator network #JLABSEMEA held its first CEO Summit at our London Innovation Centre last week. A big thank you to all the incredible innovators and thought leaders who joined us. Let's keep the momentum going! #JNJInnovation

Are you developing novel Antibody Drug Conjugates? Applications are now open for the Pitching ADC Advancements #QuickFire Challenge! Don’t miss your chance - click the link below to learn more.

Don’t miss your chance to submit your potentially groundbreaking advancements in clinical trial innovation to our Leveraging Technology to Drive Representative Clinical Trials #QuickFireChallenge by September 13th!

Innovating in Precision Medicine? Join us on July 24 to learn how we can collaborate to translate early neuroscience innovations into tangible solutions for patients. RSVP: jji.jnj/IIPM

Great news from #JNJImmunology! This strategic acquisition, facilitated by Johnson & Johnson Innovation teams in EMEA and Asia Pacific, is an excellent example of how we are able to link expertise from across the company to advance transformational early-stage innovations.

The IPO market has been showing promising signs of recovery in 2024. We've partnered with DealForma for an upcoming webinar that will cover the current state of biopharma dealmaking and investment. Register today to secure your seat! jji.jnj/3VPyR6e

Congratulations to @LociOrtho on closing their €12.8 Million #SeriesA financing round! J&J Innovation – JJDC, Inc. led with Seroba, European Innovation Council and the investment will help in the development of its #medtech InDx Implant System for thumb base joint #arthritis. jji.jnj/3zGm655

Our Innovation Ignited: Conversations in Precision Medicine webinar, dedicated to sparking cutting edge ideas in digital diagnostics for neuroscience, is just two days away. It’s not too late to join us! Register now: jji.jnj/IIPM

Did you miss out on the 2024 #BLUEKNIGHT Symposium? You can now view the Symposium on-demand and join the global conversation with innovators, investors, partners and thought leaders to catalyze the breakthrough solutions of tomorrow.

Innovators, academics, and partners – the application deadline to meet with J&J immunology experts is quickly approaching! Apply today!

BLUE KNIGHT™ has made an incredible impact over the past four years and has grown to support 46 companies from across the global community. Join us in celebrating the anniversary and the progress made. jji.jnj/4cYHkdi

Ever wondered what it takes to be a healthcare entrepreneur? We’re proud to be #AllIn with innovators like Dr. Robert Zhao, Founder and CEO of Hangzhou DAC, a company revolutionizing oncology. Watch now: jji.jnj/4fAacKI #WeAreAllIn #JNJInnovation

Do you provide small scientific companies with quality products & services? The Resource hub could be the ticket to sharing your offerings with hundreds of companies. Meet our latest sponsor: jji.jnj/4cNFGdP

From a #JLABS startup to J&J acquisition, our collaboration with Serotiny and their innovative work in designing therapeutic multi-domain proteins for the next generation of cell & gene therapies is driving biopharma innovation. Read the full story here: jji.jnj/3T5M34R

The future holds immense potential as we build on the solid foundation we've established, helping more companies succeed and contributing to a safer, healthier world." Rachel Rath & Ashim Subedee reflect on the past four years and what’s to come for BLUE KNIGHT™

Attending ESMO in Barcelona? Then come meet with our Interventional Oncology team during an evening networking reception hosted on Saturday, 14 September at the Olivia Balmes Hotel! RSVP today, spaces are limited. jji.jnj/4g3S7VH